PUBLIC NOTICE

June 16, 2022

Pursuant to 42 C.F.R. Section 447.205, public notice is hereby given for the submission of a Medicaid State Plan Amendment (SPA) 22-0005 COVID Treatment and Complications Coverage. The Division of Medicaid, in the Office of the Governor, will submit this proposed SPA to the Centers for Medicare and Medicaid Services (CMS) effective March 11, 2021, contingent upon approval from CMS, our Transmittal #22-0005.

- 1. State Plan Amendment (SPA) SPA 22-0005 is being submitted to comply with the ARP requirements for coverage of COVID-19 treatment or for a condition that may seriously complicate the treatment of COVID-19 for individuals diagnosed with or presumed to have COVID-19 during the period the individual has COVID-19. This SPA is being submitted with an 1135 waiver request to enable the effective date to comply with the ARP.
- 2. The expected annual aggregate expenditures is not known because services were not able to be identified as COVID related in historical data. The Division of Medicaid has now implemented a modifier and will be able to identify COVID related services moving forward.
- 3. The Division of Medicaid is submitting this proposed SPA to be in compliance with the American Rescue Plan.
- 4. A copy of the proposed SPA will be available in each county health department office and in the Department of Human Services office in Issaquena County for review. A hard copy can be downloaded and printed from www.medicaid.ms.gov, or requested at 601-359-2081 or by emailing at DOMPolicy@medicaid.ms.gov.
- 5. Written comments will be received by the Division of Medicaid, Office of the Governor, Office of Policy, Walter Sillers Building, Suite 1000, 550 High Street, Jackson, Mississippi 39201, or DOMPolicy@medicaid.ms.gov for thirty (30) days from the date of publication of this notice. Comments will be available for public review at the above address and on the Division of Medicaid's website at www.medicaid.ms.gov.
- 6. A public hearing on this SPA will not be held.

COVID-19 Treatment at section 1905(a)(4)(F) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

Coverage for the Treatment and Prevention of COVID

X The states assure (including preventive	es coverage of COVID-19 treatment, including specialized equipment and therapies therapies).
X The state	e assures that such coverage:
	ncludes any non-pharmacological item or service described in section 1905(a) of he Act, that is medically necessary for treatment of COVID-19;
D A	ncludes any drug or biological that is approved (or licensed) by the U.S. Food & Drug Administration (FDA) or authorized by the FDA under an Emergency Use authorization (EUA) to treat or prevent COVID-19, consistent with the applicable uthorizations;
	s provided without amount, duration or scope limitations that would otherwise pply when covered for purposes other than treatment or prevention of COVID-19;
4. Is	s provided to all categorically needy eligibility groups covered by the state that eceive full Medicaid benefits;
	s provided to the optional COVID-19 group, if applicable; and
6. Is a co	s provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(l) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such overage is not reduced by any cost sharing that would otherwise be applicable ander the state plan.
	Applies to the state's approved Alternative Benefit Plans, without any deduction, sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.
	assures compliance with the HHS COVID-19 PREP Act declarations and s, including all of the amendments to the declaration.
Additional Inf	formation (Optional):

Coverage for a Condition that May Seriously Complicate the Treatment of COVID

X The states assures coverage of treatment for a condition that may seriously complicate the treatment of COVID-19 during the period when a beneficiary is diagnosed with or is presumed to have COVID-19.
X The state assures that such coverage:
 Includes items and services, including drugs, that were covered by the state as of March 11, 2021; Is provided without amount, duration or scope limitations that would otherwise apply when covered for other purposes; Is provided to all categorically needy eligibility groups covered by the state that
receive full Medicaid benefits; 4. Is provided to the optional COVID-19 group, if applicable; and 5. Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(I) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.
Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.
X The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration.
Additional Information (Optional):
Reimbursement

_X__ The state assures that it has established state plan rates for COVID-19 treatment, including specialized equipment and therapies (including preventive therapies).

List references to Medicaid state plan payment methodologies that describe the rates for COVID-19 treatment for each applicable Medicaid benefit:

Payment methodologies for COVID-19 treatment are described in Attachment 4.19-A and 4.19-B

ipment a	Page te is establishing rates or fee schedule for COVID-19 treatment, including specialized nd therapies (including preventive therapies) pursuant to sections 1905(a)(4)(F) and
2(a)(30)(<i>i</i>	A) of the Act.
	The state's rates or fee schedule is the same for all governmental and private providers.
	The below listed providers are paid differently from the above rate schedules and payment to these providers for COVID-19 vaccines and the administration of the vaccines are described under the benefit payment methodology applicable to the provider type:
itional In	formation (Optional):

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

COVID-19 Treatment at section 1905(a)(4)(F) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

Coverage for the Treatment and I	Prevention of	f COVID
----------------------------------	---------------	---------

X The sta	ate assures that such coverage:
1.	Includes any non-pharmacological item or service described in section 1905(a) of the Act, that is medically necessary for treatment of COVID-19;
2.	Includes any drug or biological that is approved (or licensed) by the U.S. Food & Drug Administration (FDA) or authorized by the FDA under an Emergency Use Authorization (EUA) to treat or prevent COVID-19, consistent with the applicable authorizations;
3.	Is provided without amount, duration or scope limitations that would otherwise apply when covered for purposes other than treatment or prevention of COVID-19
4.	Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
5.	Is provided to the optional COVID-19 group, if applicable; and
6.	Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(l) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.
	_ Applies to the state's approved Alternative Benefit Plans, without any deduction, st sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.
	te assures compliance with the HHS COVID-19 PREP Act declarations and ons, including all of the amendments to the declaration.

<u>Coverage for a Condition that May Seriously Complicate the Treatment of COVID</u>

	sures coverage of treatment for a condition that may seriously complicate the D-19 during the period when a beneficiary is diagnosed with or is presumed to have
<u>X</u> The st	ate assures that such coverage:
2. 3. 4. 5. ————————————————————————————————	Includes items and services, including drugs, that were covered by the state as of March 11, 2021; Is provided without amount, duration or scope limitations that would otherwise apply when covered for other purposes; Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits; Is provided to the optional COVID-19 group, if applicable; and Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(I) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan. _ Applies to the state's approved Alternative Benefit Plans, without any deduction, st sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act. ate assures compliance with the HHS COVID-19 PREP Act declarations and ions, including all of the amendments to the declaration.
Additional Informa	ation (Optional):
Reimbursement	
	ures that it has established state plan rates for COVID-19 treatment, including nent and therapies (including preventive therapies).

Payment methodologies for COVID-19 treatment are described in Attachment 4.19-A and 4.19-B

List references to Medicaid state plan payment methodologies that describe the rates for

COVID-19 treatment for each applicable Medicaid benefit:

	A) of the Act.
	The state's rates or fee schedule is the same for all governmental and private providers.
	The below listed providers are paid differently from the above rate schedules a payment to these providers for COVID-19 vaccines and the administration of the vaccines are described under the benefit payment methodology applicable to the provider type:
Γ	

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.